Evenity recorded sales of $442 million in the quarter, up 29% year over year, driven by solid volume growth in the United States. Evenity sales beat the Zacks Consensus Estimate of $406.0 million ...

The U.S. Food and Drug Administration on Tuesday approved Amgen Inc's drug Evenity for the treatment of osteoporosis in postmenopausal women who are at high risk of bone fractures. More than 10 ...

With promising trial results and an FDA approval seemingly near, Amgen Inc.'s osteoporosis drug Evenity was expected to contribute at least something to the company's top line this year. But Amgen ...

The U.S. Food and Drug Administration last week approved bone-building Evenity for postmenopausal women who are at high risk of fracture, but required the label to have a boxed warning, the FDA ...

Amgen and UCB’s osteoporosis drug Evenity has finally won over the FDA, thanks to a pared-back indication in high-risk women. | Amgen and UCB’s osteoporosis drug Evenity finally won over the ...

Evenity, which was approved in 2019, is on a blockbuster trajectory. It generated sales of $787 million last year, a 48% increase from 2021. The drug is for post-menopausal women at severe risk of ...

AMGN's 14 products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieve double-digit volume growth in the first quarter.

April 15- Amgen Inc on Monday set the U.S. list price for its new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12- month course.

Evenity sales beat the Zacks Consensus Estimate of $406.0 million as well as our model estimate of $370.0 million. Prolia revenues came in at $1.1 billion, ...